Brookfield Office Stock To Go Ex-dividend Tomorrow (BPO)

NEW YORK ( TheStreet) -- The ex-dividend date for Brookfield Office Properties (NYSE: BPO) is tomorrow, February 28, 2012. Owners of shares as of market close today will be eligible for a dividend of 14 cents per share. At a price of $17.41 as of 9:30 a.m. ET, the dividend yield is 3.2%.

The average volume for Brookfield Office has been 1.8 million shares per day over the past 30 days. Brookfield Office has a market cap of $8.77 billion and is part of the financial sector and real estate industry. Shares are up 12.1% year to date as of the close of trading on Friday.

Brookfield Properties Corporation is a publicly owned real estate investment firm. The firm engages in the ownership, development, and management of premier commercial properties. It also provides ancillary real estate service businesses, such as tenant service and amenities. The company has a P/E ratio of 6.2, above the average real estate industry P/E ratio of 4.3 and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Brookfield Office as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and disappointing return on equity. You can view the full Brookfield Office Ratings Report.

See our dividend calendar or top-yielding stocks list.

null

More from Markets

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)